Astragaloside IV protects against iron loading‐induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs)

Abstract

Iron loading has been reported to be a common stress in the development of cells, and this might be related to bone loss and osteoporosis. Astragaloside IV (ASI‐IV), a pure compound derived from Radix Astragali, has been reported to exhibit cardioprotective, anti‐inflammatory, antioxidant, antiasthmatic and anticancer effects. The aim of this study was to investigate whether ASI‐IV could reverse iron loading‐induced inhibition of cell viability, proliferation, pluripotency and osteogenesis and promote adipogenesis of bone marrow mesenchymal stem cells (BMSCs). Ferric ammonium citrate (FAC) was used to stimulate iron loading conditions. ASI‐IV was observed to ameliorate the FAC‐induced reduction of cell viability, proliferation, pluripotency and osteogenesis of BMSCs. In addition, ASI‐IV could block the increased adipogenesis of BMSCs after FAC treatment. We intraperitoneally injected mice with 250 mg·kg−1 iron dextran, with or without ASI‐IV (40 mg·kg−1), for 4 weeks. ASI‐IV inhibited the iron loading‐induced bone loss of these mice. Furthermore, ASI‐IV played a protective role in iron loading‐induced abnormal differentiation of BMSCs by regulating iron homeostasis and metabolism. In summary, our study suggesteds that ASI‐IV might have potentials for development into a novel therapeutic strategy for the treatment of iron loading‐induced abnormal differentiation of BMSCs and osteoporosis.

Therapeutic Effect of Astragali Radix Extract Injection Combined with Bone Marrow Mesenchymal Stem Cells in Bleomycin-Induced Pulmonary Fibrotic Rats

“…After transplantation, BMSCs can migrate to damaged lung tissues, modulate immune cell function, reduce local inflammation, and inhibit fibrosis through various pathways such as paracrine secretion. Astragaloside IV [ 42 ] and astragaloside polysaccharides both promote the proliferation and differentiation of BMSCs after transplantation [ 43 ]. The present study found that the therapeutic effects of AI with and without BMSCs in BLM rats are due to the modulating effects of active Astragalus polysaccharides on BMSCs.…”

A potential function for MicroRNA-124 in normal and pathological bone conditions

“…A study by Cao et al showed that astragaloside IV (AST-IV) helps human BMSCs grow and differentiate into osteogenic cells via the miR-124-3p.1/STAT3 axis. AST-IV is one of the main chemicals that comes from extracts of Astragalus membranaceus [ 60 ] and helps protect and differentiate BMSCs [ 61 ]. AST-IV promotes the cell cycle, viability, and osteogenic differentiation of human BMSCs.…”

Notoginsenoside R1 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERα/GSK‐3β/β‐catenin signalling pathway

“…Bone marrow mesenchymal stem cells (BMSCs), isolated from the bone marrow of mammals, are an ideal source of MSCs which possess multidirectional differentiation potency 6 . BMSCs have osteogenic differentiation potential, thereby promoting bone formation 7 .…”

“…4,5 Hence, finding more effective approaches for promoting bone injury repair is still greatly needed.Bone marrow mesenchymal stem cells (BMSCs), isolated from the bone marrow of mammals, are an ideal source of MSCs which possess multidirectional differentiation potency. 6 BMSCs have osteogenic differentiation potential, thereby promoting bone formation. 7 Increasing evidence…”